US · CYRX · INTEGRATED FREIGHT & LOGISTICS
Cryoport, Inc. (CYRX) intrinsic value and stock valuation
$19.05as of 2026-11-21 · Mkt cap 768.64M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cryoport, Inc. DCF and intrinsic value
InvestorsCraft values CYRX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from CYRX’s statements →
Cryoport, Inc. Graham Number
Graham Number: $18.79d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $176.2M | $233.3M | $237.3M | $222.6M | $222.6M |
| Operating income | -$-36.81M | -$-115.16M | -$-31.9M | -$-17.83M | -$-17.83M |
| Net income | $78.3M | -$-99.59M | -$-37.33M | -$-275.53M | -$-275.53M |
| EPSd | $1.56M | -$-2.04M | -$-761.99K | -$-6M | -$-6M |
| Operating cash flow | -$-8.58M | -$-16.32M | -$-760K | -$-1.85M | $8.13M |
| Capital expenditure | -$-19.5M | -$-17.25M | -$-44.9M | -$-24.2M | -$-25.01M |
| Free cash flow | -$-28.09M | -$-33.58M | -$-45.66M | -$-26.05M | -$-16.88M |
| Total assets | $765M | $703.5M | $957.7M | $1.04B | $1.11B |
| Total debt | $230.7M | $250.7M | $416M | $435.9M | $427.1M |
| Net debt | -$-19.78M | $205.4M | $369.7M | $399.3M | $288M |
| Total equity | $502.6M | $401.9M | $489M | $555.8M | $641.8M |
| Cash and short-term investments | $411.2M | $261.8M | $456.8M | $523.3M | $628.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $176.2M | $233.3M | $237.3M | $222.6M | $222.6M |
| Cost of revenue | $93.1M | $133.9M | $133.4M | $126M | $126M |
| Gross profit | $83.1M | $99.3M | $103.9M | $96.6M | $96.6M |
| Research and development expenses | $17M | $18M | $15.7M | $16.8M | $16.8M |
| Selling, general and administrative expenses | $102.8M | $146.9M | $120.1M | $97.6M | $97.6M |
| Other expenses | $0.00 | $49.6M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $119.9M | $214.5M | $135.8M | $114.4M | $114.4M |
| Cost and expenses | $213M | $348.4M | $269.2M | $240.4M | $240.4M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $2.36M | $5.5M | $6.14M | $4.69M | $4.69M |
| Depreciation and amortization | $27.7M | $27.5M | $22.8M | $20.3M | $20.3M |
| Ebitda | -$-2.1M | -$-66.36M | -$-6.19M | -$-248.91M | -$-248.91M |
| Operating income | -$-36.81M | -$-115.16M | -$-31.9M | -$-17.83M | -$-17.83M |
| Total other income/expenses, net | $4.64M | $15.8M | -$-3.19M | -$-256.01M | -$-256.01M |
| Income before tax | -$-32.17M | -$-99.35M | -$-35.09M | -$-273.84M | -$-273.84M |
| Income tax expense | $1.8M | $240K | $2.24M | $1.69M | $1.69M |
| Net income | $78.3M | -$-99.59M | -$-37.33M | -$-275.53M | -$-275.53M |
| Weighted average shares outstanding | $50.1M | $48.7M | $49M | $45.9M | $45.9M |
| Weighted average diluted shares outstanding | $50.1M | $48.7M | $49M | $45.9M | $45.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $411.2M | $261.8M | $456.8M | $523.3M | $628.8M |
| Net receivables | $33.4M | $45.8M | $42.1M | $43.9M | $39.4M |
| Inventory | $23.2M | $22.5M | $26.2M | $27.7M | $16.5M |
| Total current assets | $476.2M | $341.6M | $535.1M | $604.2M | $693.5M |
| Property, plant and equipment, net | $125.2M | $136M | $117.5M | $90.5M | $69.7M |
| Goodwill and intangible assets | $160.5M | $222.1M | $302.8M | $342.1M | $348.4M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $288.8M | $361.9M | $422.6M | $434.6M | $419.5M |
| Total assets | $765M | $703.5M | $957.7M | $1.04B | $1.11B |
| Accounts payable | $15.3M | $26.2M | $26.1M | $27.1M | $28.6M |
| Short-term debt | $189.8M | $20.4M | $5.81M | $3.91M | $3.6M |
| Deferred revenue | $940K | $1.11M | $1.31M | $440K | $550K |
| Total current liabilities | $219M | $64.6M | $45.6M | $40.9M | $42.7M |
| Long-term debt | $40.9M | $230.4M | $410.2M | $432M | $423.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $43.3M | $237M | $423.1M | $442.1M | $428.5M |
| Capital lease obligations | $44.4M | $51.2M | $36M | $28.8M | $21.8M |
| Total liabilities | $262.4M | $301.6M | $468.7M | $482.9M | $471.1M |
| Common stock | $50K | $50K | $50K | $50K | $50K |
| Retained earnings | -$-688.88M | -$-757.17M | -$-642.42M | -$-542.83M | -$-467.54M |
| Accumulated other comprehensive income (loss) | -$-3.48M | -$-20.93M | -$-26.07M | -$-34.55M | -$-1.24M |
| Total equity | $502.6M | $401.9M | $489M | $555.8M | $641.8M |
| Total investments | $160.7M | $216.5M | $410.4M | $486.7M | $489.7M |
| Total debt | $230.7M | $250.7M | $416M | $435.9M | $427.1M |
| Net debt | -$-19.78M | $205.4M | $369.7M | $399.3M | $288M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $78.3M | -$-114.76M | -$-99.59M | -$-37.33M | -$-275.53M |
| Depreciation and amortization | $27.7M | $30.8M | $27.5M | $22.8M | $20.3M |
| Stock-based compensation | $11M | $19.7M | $22.8M | $20.1M | $15.4M |
| Change in working capital | -$-13.69M | -$-8.61M | $780K | -$-32.07M | -$-6.96M |
| Accounts receivable | -$-6.53M | -$-4.15M | $3.67M | -$-4.14M | -$-7.27M |
| Inventory | -$-2.19M | $3.25M | $1.51M | -$-14.2M | -$-5.98M |
| Accounts payable | -$-3.46M | -$-80K | -$-2.77M | -$-6.48M | $2.87M |
| Net cash provided by operating activities | -$-8.58M | -$-16.32M | -$-760K | -$-1.85M | $8.13M |
| Investments in property, plant and equipment | -$-16.44M | -$-17.25M | -$-38.78M | -$-22.11M | -$-23.88M |
| Acquisitions, net | $210.2M | $0.00 | -$-7.34M | -$-6.55M | -$-5.54M |
| Net cash used for investing activities | $250.3M | $176.8M | $36.1M | -$-59.68M | -$-469.25M |
| Common stock issued | $3.97M | $2.79M | $1.48M | $2.05M | $527.7M |
| Common stock repurchased | -$-10.01M | $0.00 | $0.00 | -$-37.96M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-21.07M | -$-161.53M | -$-23.8M | -$-39.17M | $564.3M |
| Net change in cash | $205.2M | -$-1.06M | $9.75M | -$-102.51M | $102.2M |
| Cash at end of period | $250.5M | $45.3M | $46.4M | $36.6M | $139.1M |
| Operating cash flow | -$-8.58M | -$-16.32M | -$-760K | -$-1.85M | $8.13M |
| Capital expenditure | -$-19.5M | -$-17.25M | -$-44.9M | -$-24.2M | -$-25.01M |
| Free cash flow | -$-28.09M | -$-33.58M | -$-45.66M | -$-26.05M | -$-16.88M |
Line items
Line items
Line items
About Cryoport, Inc.
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
- CEO
- Jerrell W. Shelton
- Employees
- 688
- Beta
- 1.89
Explore
Frequently asked questions
What is the intrinsic value of Cryoport, Inc. (CYRX)?
Cryoport, Inc. (CYRX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CYRX undervalued?
CYRX trades at a price of $19.05 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.